AI Article Synopsis
- Malignant pleural mesothelioma (MM) is a severe cancer often caused by asbestos exposure and is typically diagnosed at later stages.
- A 58-year-old mason experienced symptoms such as chest pain, shortness of breath, and weight loss, leading to imaging tests that showed abnormalities in the pleura and lymph nodes.
- Despite initial negative biopsy results, MM was confirmed through a targeted ultrasound-guided biopsy of a lymph node, using specific staining to identify the cancer cells.
Article Abstract
Malignant pleural mesothelioma, an aggressive neoplasm frequently linked to asbestos exposure, is often detected at an advanced stage. This report details the case of a 58-year-old mason who presented with left-sided chest pain, and shortness of breath, accompanied by weight loss for a month. A positron emission tomography (PET) scan revealed increased uptake along the pleural surface, as well as in several mediastinal lymph nodes and the left supraclavicular lymph node. Thoracoscopy revealed the presence of multiple nodules on the costal pleura. Despite repeated negative results from pleural effusion cytology, cell block analysis, and pleural biopsies, the diagnosis of malignant mesothelioma (MM) was ultimately established through an ultrasound-guided (USG) biopsy of the left supraclavicular lymph node, with immunohistochemical confirmation using calretinin.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11455275 | PMC |
| http://dx.doi.org/10.7759/cureus.68718 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Malignant Sclerosing Biphasic Mesothelioma: first repport in a dog.
Vet Ital
January 2025
Hospital Veterinário Universitário, Departamento de Patologia Animal, Universidade Santo Amaro (UNISA), São Paulo, SP, Brazil.
Malignant Mesothelioma is a malignant tumor arising from the peritoneum, pleura or pericardium. It's rarely reported in dogs. Currently, there are two classifications of neoplasia: one for human medicine and other for veterinary.
View Article and Find Full Text PDFEngineered Cellular Therapies for the Treatment of Thoracic Cancers.
Cancers (Basel)
December 2024
Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Thoracic malignancies (lung cancers and malignant pleural mesothelioma) are prevalent worldwide and are associated with high morbidity and mortality. Effective treatments are needed for patients with advanced disease. Cell therapies are a promising approach to the treatment of advanced cancers that make use of immune effector cells that have the ability to mediate antitumor immune responses.
View Article and Find Full Text PDFModeling Malignant Mesothelioma in Genetically Engineered Mice.
Curr Protoc
January 2025
Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Mesothelioma is a lethal cancer of the serosal lining of the body cavities. Risk factors include environmental and genetic factors. Asbestos exposure is considered the principal environmental risk factor, but other carcinogenic mineral fibers, such as erionite, also have a causal role.
View Article and Find Full Text PDFRare Primary Pericardial Mesothelioma on an [18F]FDG PET/CT Scan and Its Postchemotherapy Response Evaluation.
Indian J Nucl Med
November 2024
Department of Nuclear Medicine and PET CT, Bombay Hospital and Medical Research Centre, Mumbai, Maharashtra, India.
Primary pericardial mesothelioma is a highly aggressive and rare neoplasm that arises from the pericardial mesothelial cell and has a poor prognosis. The diagnosis is usually established by histological and immunohistochemical studies. Malignant mesothelioma most frequently occurs from the pleura (90%), less frequently from the peritoneum and pericardium (6%-10%), and very rarely from the tunica vaginalis in the testis.
View Article and Find Full Text PDFPrognostic Indicator for Pleural Mesothelioma.
Ann Thorac Surg Short Rep
December 2024
Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Background: In malignant pleural mesothelioma), it is difficult to evaluate the degree of tumor progression using imaging findings. It is essential to develop an objective index that is independent of imaging findings and useful for assessing the degree of tumor progression and indications for surgery.
Methods: We retrospectively evaluated the data of 79 patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy or pleurectomy/decortication at our institution between 1999 and 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!